NOTV
Inotiv·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NOTV
Inotiv, Inc.
A leading contract research organization that provides contract-based bioanalytical, preclinical research services to pharmaceutical and drug development company
Life Science Tools and Services
--
11/24/1997
NASDAQ Stock Exchange
1,977
09-30
Common stock
2701 Kent Avenue, West Lafayette, Indiana 47906
--
Inotiv, Inc., is an international contract research organization providing drug discovery and development services. The company's customers and partners include pharmaceutical, biotechnology, academic and government agencies, etc. The company utilizes innovative technologies and products, as well as its commitment to quality, to help customers and partners accelerate the development of safe and effective therapies and maximize the return on investment in their research and development. The company offers an efficient variable cost plan to replace its customers' internal product development plans. The Company outsources development work to reduce overhead through U.S. Food and Drug Administration (" FDA ") approval. The company generates revenue from selling its research services and drug development tools, both of which focus on determining the safety and efficacy of drugs. The company has been engaged in drugs to treat a variety of therapeutic areas for more than 35 years, and has been conducting research in Indiana since its establishment in 1974.
Earnings Call
Q3/2025
Estimate EPS-0.15
Actual EPS-0.51
Estimate Revenue127.05M
Actual Revenue130.68M
Inotiv's Q3 2025: Navigating Contradictions in Cancellations, NIH Funding, and Profitability
Aug 07,2025 03:21
Earnings Decrypt
Earnings Decrypt
Q4/2025
Estimate EPS-0.08
Actual EPS-0.25
Estimate Revenue137.50M
Actual Revenue138.10M
Inotiv's Q4 2025 Earnings Call: Contradictions Emerge on Cancellation Trends, FDA Guidance, Cybersecurity Impact, NHP Pricing, and DSA Margins
Dec 04,2025 07:31
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NOTV has released its 2025 Q4 earnings. EPS was reported at -0.25, versus the expected -0.08, missing expectations. The chart below visualizes how NOTV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NOTV has released its 2025 Q3 earnings report, with revenue of 130.68M, reflecting a YoY change of 23.54%, and net profit of -17.58M, showing a YoY change of 32.62%. The Sankey diagram below clearly presents NOTV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
